149777-72-0

Upstream product

• 37942-01-1 5-bromo-2-methoxyphenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 7368-78-7 4-bromoguaiacol 

Downstream Products

• 489422-91-5 tert-butyl[4-(3,5-dibromobenzo[b]furan-2-yl)-2-methoxyphenoxy]dimethylsilane 
• 489422-97-1 {4-[3-bromo-5-(prop-1-enyl)benzo[b]furan-2-yl]-2-methoxyphenoxy}-tert-butyldimethylsilane 
• 1574527-14-2 C₃₉H₆₃B₃O₉Si₃ 
• 1186138-10-2 C₁₃H₂₁LiO₂Si 
• 489423-02-1 (E)-tert-butyl{2-methoxy-4-[3-methyl-5-(prop-1-enyl)benzo[b]furan-2-yl]phenoxy}dimethylsilane 
• 41744-28-9 eupomatenoid-5 
• 891182-95-9 (7R,8R,7'S,8'R)-4-hydroxy-3-methoxy-4'-hydroxy-3'-methoxy-7,7'-epoxylignan 
• 954425-21-9 (-)-futokadsurin A 

Relevant academic research and scientific papers

Total synthesis of 8,14-dihydromorphinandienone alkaloids

A collective synthesis of 8,14-dihydronorsalutaridine, 8,14- dihydrosalutaridine, norisosinomenine, and isosinomenine is reported. The strategy provides direct access to the correct oxidation level of the products. The combination of an organocatalyst guanidine superbase, a tertiary amine base, and a dehydrating agent was necessary for the successful Henry-Michael- dehydration cascade to form the phenanthrene motif. The required selective aliphatic nitro reduction could only be achieved under heterogeneous transfer-hydrogenation conditions.

Kumada-Corriu cross coupling route to the anti-cancer agent combretastatin A-4

A short and efficient synthesis of the anticancer agent combretastatin A-4 was accomplished from inexpensive starting materials using the iron-catalyzed cross-coupling of a Grignard reagent and a bromostilbene as the key step. Copyright Taylor & Francis Group, LLC.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.

Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia

We previously reported Chalcone-4 (1) that binds the chemokine CXCL12, not its cognate receptors CXCR4 or CXCR7, and neutralizes its biological activity. However, this neutraligand suffers from limitations such as poor chemical stability, solubility, and oral activity. Herein, we report on the discovery of pyrimidinone 57 (LIT-927), a novel neutraligand of CXCL12 which displays a higher solubility than 1 and is no longer a Michael acceptor. While both 1 and 57 reduce eosinophil recruitment in a murine model of allergic airway hypereosinophilia, 57 is the only one to display inhibitory activity following oral administration. Thereby, we here describe 57 as the first orally active CXCL12 neutraligand with anti-inflammatory properties. Combined with a high binding selectivity for CXCL12 over other chemokines, 57 represents a powerful pharmacological tool to investigate CXCL12 physiology in vivo and to explore the activity of chemokine neutralization in inflammatory and related diseases.

Structural revision of the hancock alkaloid (-)-galipeine

The 1H and 13C NMR data of synthetic samples of (S)-N1-methyl-2- [2′-(3″-hydroxy-4″-methoxyphenyl)ethyl]-1,2,3,4-tetrahydroquinoline, the originally proposed structure of the Hancock alkaloid (-)-galipeine, do not match those of the natural product. Herein, the preparation of the regioisomer (S)-N1-methyl-2-[2′- (3″-methoxy-4″-hydroxyphenyl)ethyl]-1,2,3,4-tetrahydroquinoline is reported, the 1H and 13C NMR data of which are in excellent agreement with those of (-)-galipeine. Comparison of specific rotation data enables assignment of the absolute (S)- configuration of the alkaloid, and together, these data engender the structural revision of (-)-galipeine to (S)-N1-methyl-2-[2′-(3″-methoxy-4″-hydroxyphenyl)ethyl]- 1,2,3,4-tetrahydroquinoline.